Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies. It also engages in the preclinical development of other drug candidates, including other STAT3 inhibitors and compounds targeting the metabolism of tumors. The company also has a strategic collaboration with the University of Bergen to develop immune stimulation drug; and the Emory University to enable expanded cancer research on WP1066 molecule for the treatment of medulloblastoma, a pediatric malignant primary brain tumor. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MBRX
Previous Symbol
CUSIPN/A
Phone713-300-5160
Debt
Debt-to-Equity RatioN/A
Current Ratio3.00
Quick Ratio3.00
Price-To-Earnings
Trailing P/E Ratio-2.60
Forward P/E Ratio-2.24
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.81 per share
Price / Book1.52
Profitability
EPS (Most Recent Fiscal Year)($0.47)
Net Income$-9,800,000.00
Net MarginsN/A
Return on Equity-79.50%
Return on Assets-61.73%
Miscellaneous
Employees8
Outstanding Shares27,130,000
Market Cap$35 million
OptionableNot Optionable
Moleculin Biotech (NASDAQ:MBRX) Frequently Asked Questions
What is Moleculin Biotech's stock symbol?
Moleculin Biotech trades on the NASDAQ under the ticker symbol "MBRX."
How were Moleculin Biotech's earnings last quarter?
Moleculin Biotech Inc (NASDAQ:MBRX) issued its earnings results on Tuesday, November, 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.13) by $0.05. View Moleculin Biotech's Earnings History.
When is Moleculin Biotech's next earnings date?
What price target have analysts set for MBRX?
2 brokerages have issued 12 month price targets for Moleculin Biotech's stock. Their predictions range from $3.00 to $8.00. On average, they anticipate Moleculin Biotech's share price to reach $5.50 in the next year. This suggests a possible upside of 347.2% from the stock's current price. View Analyst Price Targets for Moleculin Biotech.
What is the consensus analysts' recommendation for Moleculin Biotech?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Moleculin Biotech in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Moleculin Biotech.
Has Moleculin Biotech been receiving favorable news coverage?
Media stories about MBRX stock have trended somewhat positive on Tuesday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Moleculin Biotech earned a news sentiment score of 1.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an impact on the company's share price in the next several days.
Are investors shorting Moleculin Biotech?
Moleculin Biotech saw a decrease in short interest in October. As of October 31st, there was short interest totalling 740,559 shares, a decrease of 29.4% from the October 15th total of 1,048,748 shares. Based on an average daily trading volume, of 161,994 shares, the short-interest ratio is currently 4.6 days. Currently, 3.7% of the shares of the company are short sold. View Moleculin Biotech's Current Options Chain.
Who are some of Moleculin Biotech's key competitors?
Some companies that are related to Moleculin Biotech include Cerecor (CERC), Galmed Pharmaceuticals (GLMD), Adamis Pharmaceuticals (ADMP), Menlo Therapeutics (MNLO), DURECT (DRRX), Correvio Pharma (CORV), XOMA (XOMA), Catalyst Biosciences (CBIO), Selecta Biosciences (SELB), Sesen Bio (SESN), Syndax Pharmaceuticals (SNDX), Mersana Therapeutics (MRSN), Sol Gel Technologies (SLGL), Spero Therapeutics (SPRO) and Imprimis Pharmaceuticals (IMMY).
Who are Moleculin Biotech's key executives?
Moleculin Biotech's management team includes the folowing people:
- Mr. Walter V. Klemp, Founder, Chairman, CEO & Pres (Age 58)
- Mr. Jonathan P. Foster, CFO & Exec. VP (Age 54)
- Dr. Donald H. Picker, Chief Scientific Officer (Age 72)
- Ms. Jacqueline Northcut, Consultant (Age 56)
- Dr. Waldemar Priebe, Co-Founder and Chairman of Scientific Advisory Board
How do I buy shares of Moleculin Biotech?
Shares of MBRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Moleculin Biotech's stock price today?
One share of MBRX stock can currently be purchased for approximately $1.23.
How big of a company is Moleculin Biotech?
Moleculin Biotech has a market capitalization of $35 million. The company earns $-9,800,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. Moleculin Biotech employs 8 workers across the globe.
What is Moleculin Biotech's official website?
How can I contact Moleculin Biotech?
Moleculin Biotech's mailing address is 2575 WEST BELLFORT SUITE 333, HOUSTON TX, 77054. The company can be reached via phone at 713-300-5160.
MarketBeat Community Rating for Moleculin Biotech (NASDAQ MBRX)
MarketBeat's community ratings are surveys of what our community members think about Moleculin Biotech and other stocks. Vote "Outperform" if you believe MBRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
